Extended Low-Dose Apixaban and Superficial Vein Thrombosis
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.
Authors
- Antoine Bejjani (ORCID: https://orcid.org/0000-0002-8975-7514)
- Behnood Bikdeli (ORCID: https://orcid.org/0000-0003-1428-879X)
- Umberto Campia (ORCID: https://orcid.org/0000-0002-7894-3565)
- Darsiya Krishnathasan (ORCID: https://orcid.org/0000-0002-5405-2733)
- Mariana Pfeferman (ORCID: https://orcid.org/0000-0002-7486-4915)
- Heather Hogan
- Nicole Porio (ORCID: https://orcid.org/0009-0007-2786-9821)
- Ankur Pandey (ORCID: https://orcid.org/0000-0003-2281-063X)
- Lisa Rosenbaum
- Ruth Morrison
- Junyang Lou
- Sina Rashedi
- Piotr S. Sobieszczyk
- Marie Gerhard-Herman
- Zhou Lan
- Candrika D. Khairani
- Gregory Piazza
- John Fanikos
- Samuel Z. Goldhaber
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Yale New Haven Hospital (US)
- Harvard University (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2026-03-29
- DOI
- https://doi.org/10.1001/jamacardio.2026.0151
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 30.07